<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103960</url>
  </required_header>
  <id_info>
    <org_study_id>1235.29</org_study_id>
    <nct_id>NCT01103960</nct_id>
  </id_info>
  <brief_title>An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy</brief_title>
  <official_title>8 Week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80mg+ Amlodipine 5 mg vs. Amlodipine 5mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 5mg Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objectives of this trial is to demonstrate that the fixed-dose combination of
      telmisartan 80mg plus amlodipine 5mg (T80/A5) is superior to amlodipine 5mg (A5) in reducing
      seated trough diastolic blood pressure (DBP) at 8 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in DBP After 8 Weeks of Treatment</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Seated trough DBP after 8 weeks or last observation carried forward (LOCF). Analysis will be adjusted for treatment, country, and baseline measurement of endpoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in DBP After 8 Weeks of Treatment in Chinese Patients</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Seated trough DBP after 8 weeks or LOCF in Chinese patients. Analysis will be adjusted for treatment and baseline measurement of endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SBP After 8 Weeks of Treatment</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Seated trough SBP after 8 weeks or LOCF. Analysis will be adjusted for treatment, country, and baseline measurement of endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBP and SBP Control and Response After 8 Weeks of Treatment</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>DBP control is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP &lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=10mmHg. SBP response is defined as SBP&lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=15mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients in Blood Pressure Categories Over Time</measure>
    <time_frame>8 weeks</time_frame>
    <description>BP optimal: SBP &lt;120 mmHg and DBP &lt;80 mmHg, BP normal: SBP &lt;130 mmHg and DBP &lt;85 mmHg but not optimal, BP high-normal: SBP &lt;140 mmHg and DBP &lt;90 mmHg but not normal. Grade 1 hypertension: SBP &lt;160 mmHg and DBP &lt;100 mmHg but not high-normal, Grade 2 hypertension: SBP &lt;180 mmHg and DBP &lt;110 mmHg but not grade 1, Grade 3 hypertension: SBP &gt;=180 mmHg or DBP &gt;=110 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DBP After 4 Weeks of Treatment</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Seated trough DBP after 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SBP After 4 Weeks of Treatment</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Seated trough SBP after 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBP and SBP Control and Response After 4 Weeks of Treatment</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>DBP control is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP &lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=10mmHg. SBP response is defined as SBP&lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=15mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients in Blood Pressure Categories at 4 Weeks</measure>
    <time_frame>4 weeks</time_frame>
    <description>BP optimal: SBP &lt;120 mmHg and DBP &lt;80 mmHg, BP normal: SBP &lt;130 mmHg and DBP &lt;85 mmHg but not optimal, BP high-normal: SBP &lt;140 mmHg and DBP &lt;90 mmHg but not normal. Grade 1 hypertension: SBP &lt;160 mmHg and DBP &lt;100 mmHg but not high-normal, Grade 2 hypertension: SBP &lt;180 mmHg and DBP &lt;110 mmHg but not grade 1, Grade 3 hypertension: SBP &gt;=180 mmHg or DBP &gt;=110 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Relevant Abnormalities for Physical Examination, Pulse Rate, Laboratory Parameters and ECG.</measure>
    <time_frame>From drug administration until end of treatment plus one day</time_frame>
    <description>Clinically relevant abnormalities for Physical examination, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">324</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Telmisartan80mg+Amlodipine5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amlodipine 5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan80mg+Amlodipine5mg</intervention_name>
    <description>combination therapy</description>
    <arm_group_label>Telmisartan80mg+Amlodipine5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine 5mg</intervention_name>
    <description>monotherapy</description>
    <arm_group_label>amlodipine 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan80mg+Amlodipine 5mg</intervention_name>
    <description>combination therapy</description>
    <arm_group_label>amlodipine 5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. diagnosis of essential hypertension

          2. failure to respond adequately to six weeks treatment with amlodipine 5 mg monotherapy

          3. provision of written informed consent

        Exclusion criteria:

        1. clinical conditions which, in the opinion of the investigator, would not allow safe
        completion of the protocol and safe administration of telmisartan and amlodipine for the
        planned duration of this trial (e.g. populations where labeling of either product
        recommends against its utilization)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1235.29.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.29.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.29.86006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.29.86013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.29.86014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.29.86012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.29.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.29.86009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.29.86010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.29.86011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.29.86007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.29.86008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.29.60017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johor</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.29.60016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.29.63018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Metro Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.29.63019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Malaysia</country>
    <country>Philippines</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2010</study_first_posted>
  <results_first_submitted>August 21, 2012</results_first_submitted>
  <results_first_submitted_qc>August 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 20, 2012</results_first_posted>
  <last_update_submitted>June 17, 2014</last_update_submitted>
  <last_update_submitted_qc>June 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Whilst there were 324 patients randomised and treated, there were only 314 in the Full analysis set (FAS).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A5 Alone</title>
          <description>Amlodipine 5mg monotherapy</description>
        </group>
        <group group_id="P2">
          <title>T80/A5</title>
          <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164">Randomised and treated.</participants>
                <participants group_id="P2" count="160">Randomised and treated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="159">Completed study medication.</participants>
                <participants group_id="P2" count="158">Completed study medication.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A5 Alone</title>
          <description>Amlodipine 5mg monotherapy</description>
        </group>
        <group group_id="B2">
          <title>T80/A5</title>
          <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="159"/>
            <count group_id="B2" value="155"/>
            <count group_id="B3" value="314"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" spread="9.7"/>
                    <measurement group_id="B2" value="52.4" spread="8.7"/>
                    <measurement group_id="B3" value="52.4" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure (DBP)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.84" spread="6.43"/>
                    <measurement group_id="B2" value="97.21" spread="5.46"/>
                    <measurement group_id="B3" value="97.53" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure (SBP)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146.27" spread="11.15"/>
                    <measurement group_id="B2" value="146.44" spread="12.20"/>
                    <measurement group_id="B3" value="146.35" spread="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in DBP After 8 Weeks of Treatment</title>
        <description>Seated trough DBP after 8 weeks or last observation carried forward (LOCF). Analysis will be adjusted for treatment, country, and baseline measurement of endpoint.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Full analysis set (FAS) defined as patients randomised, treated, with a baseline endpoint measurement and at least one post-dose endpoint measurement during the double blind (DB) phase.</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Alone</title>
            <description>Amlodipine 5mg monotherapy</description>
          </group>
          <group group_id="O2">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DBP After 8 Weeks of Treatment</title>
          <description>Seated trough DBP after 8 weeks or last observation carried forward (LOCF). Analysis will be adjusted for treatment, country, and baseline measurement of endpoint.</description>
          <population>Full analysis set (FAS) defined as patients randomised, treated, with a baseline endpoint measurement and at least one post-dose endpoint measurement during the double blind (DB) phase.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.19" spread="0.93"/>
                    <measurement group_id="O2" value="-12.38" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A5 minus T80/A5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>This was the first step in the closed testing procedure of multiple endpoints. The p-value was &lt;0.05 so this test was considered confirmatory. Proceeding to the next step was allowed, testing the same endpoint in the subgroup of Chinese patients.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.1881</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8030</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.6082</ci_lower_limit>
            <ci_upper_limit>3.7681</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in DBP After 8 Weeks of Treatment in Chinese Patients</title>
        <description>Seated trough DBP after 8 weeks or LOCF in Chinese patients. Analysis will be adjusted for treatment and baseline measurement of endpoint.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>FAS with LOCF and further restricted to the Chinese subgroup</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Alone</title>
            <description>Amlodipine 5mg monotherapy</description>
          </group>
          <group group_id="O2">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DBP After 8 Weeks of Treatment in Chinese Patients</title>
          <description>Seated trough DBP after 8 weeks or LOCF in Chinese patients. Analysis will be adjusted for treatment and baseline measurement of endpoint.</description>
          <population>FAS with LOCF and further restricted to the Chinese subgroup</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.85" spread="0.63"/>
                    <measurement group_id="O2" value="-10.77" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A5 minus T80/A5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <p_value_desc>This was the second step in the closed testing procedure of multiple endpoints. The p-value was again &lt;0.05 so this test was also considered confirmatory.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.9195</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.1443</ci_lower_limit>
            <ci_upper_limit>3.6947</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SBP After 8 Weeks of Treatment</title>
        <description>Seated trough SBP after 8 weeks or LOCF. Analysis will be adjusted for treatment, country, and baseline measurement of endpoint.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>FAS with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Alone</title>
            <description>Amlodipine 5mg monotherapy</description>
          </group>
          <group group_id="O2">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SBP After 8 Weeks of Treatment</title>
          <description>Seated trough SBP after 8 weeks or LOCF. Analysis will be adjusted for treatment, country, and baseline measurement of endpoint.</description>
          <population>FAS with LOCF</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.66" spread="1.30"/>
                    <measurement group_id="O2" value="-16.15" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A5 minus T80/A5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.4879</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1217</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.2807</ci_lower_limit>
            <ci_upper_limit>6.6950</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DBP and SBP Control and Response After 8 Weeks of Treatment</title>
        <description>DBP control is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP &lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=10mmHg. SBP response is defined as SBP&lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=15mmHg.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>FAS with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Alone</title>
            <description>Amlodipine 5mg monotherapy</description>
          </group>
          <group group_id="O2">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>DBP and SBP Control and Response After 8 Weeks of Treatment</title>
          <description>DBP control is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP &lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=10mmHg. SBP response is defined as SBP&lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=15mmHg.</description>
          <population>FAS with LOCF</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients in Blood Pressure Categories Over Time</title>
        <description>BP optimal: SBP &lt;120 mmHg and DBP &lt;80 mmHg, BP normal: SBP &lt;130 mmHg and DBP &lt;85 mmHg but not optimal, BP high-normal: SBP &lt;140 mmHg and DBP &lt;90 mmHg but not normal. Grade 1 hypertension: SBP &lt;160 mmHg and DBP &lt;100 mmHg but not high-normal, Grade 2 hypertension: SBP &lt;180 mmHg and DBP &lt;110 mmHg but not grade 1, Grade 3 hypertension: SBP &gt;=180 mmHg or DBP &gt;=110 mmHg.</description>
        <time_frame>8 weeks</time_frame>
        <population>FAS with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Alone</title>
            <description>Amlodipine 5mg monotherapy</description>
          </group>
          <group group_id="O2">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Blood Pressure Categories Over Time</title>
          <description>BP optimal: SBP &lt;120 mmHg and DBP &lt;80 mmHg, BP normal: SBP &lt;130 mmHg and DBP &lt;85 mmHg but not optimal, BP high-normal: SBP &lt;140 mmHg and DBP &lt;90 mmHg but not normal. Grade 1 hypertension: SBP &lt;160 mmHg and DBP &lt;100 mmHg but not high-normal, Grade 2 hypertension: SBP &lt;180 mmHg and DBP &lt;110 mmHg but not grade 1, Grade 3 hypertension: SBP &gt;=180 mmHg or DBP &gt;=110 mmHg.</description>
          <population>FAS with LOCF</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BP optimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP high-normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DBP After 4 Weeks of Treatment</title>
        <description>Seated trough DBP after 4 weeks.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Alone</title>
            <description>Amlodipine 5mg monotherapy</description>
          </group>
          <group group_id="O2">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DBP After 4 Weeks of Treatment</title>
          <description>Seated trough DBP after 4 weeks.</description>
          <population>FAS with LOCF</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.51" spread="6.80"/>
                    <measurement group_id="O2" value="-9.41" spread="7.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SBP After 4 Weeks of Treatment</title>
        <description>Seated trough SBP after 4 weeks.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Alone</title>
            <description>Amlodipine 5mg monotherapy</description>
          </group>
          <group group_id="O2">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SBP After 4 Weeks of Treatment</title>
          <description>Seated trough SBP after 4 weeks.</description>
          <population>FAS with LOCF</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.19" spread="11.45"/>
                    <measurement group_id="O2" value="-12.10" spread="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DBP and SBP Control and Response After 4 Weeks of Treatment</title>
        <description>DBP control is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP &lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=10mmHg. SBP response is defined as SBP&lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=15mmHg.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Alone</title>
            <description>Amlodipine 5mg monotherapy</description>
          </group>
          <group group_id="O2">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>DBP and SBP Control and Response After 4 Weeks of Treatment</title>
          <description>DBP control is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP &lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP &lt;90 mmHg or &lt;80 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=10mmHg. SBP response is defined as SBP&lt;140 mmHg or &lt;130 mmHg in patients with diabetes or renal impairment or a reduction from baseline &gt;=15mmHg.</description>
          <population>FAS with LOCF</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients in Blood Pressure Categories at 4 Weeks</title>
        <description>BP optimal: SBP &lt;120 mmHg and DBP &lt;80 mmHg, BP normal: SBP &lt;130 mmHg and DBP &lt;85 mmHg but not optimal, BP high-normal: SBP &lt;140 mmHg and DBP &lt;90 mmHg but not normal. Grade 1 hypertension: SBP &lt;160 mmHg and DBP &lt;100 mmHg but not high-normal, Grade 2 hypertension: SBP &lt;180 mmHg and DBP &lt;110 mmHg but not grade 1, Grade 3 hypertension: SBP &gt;=180 mmHg or DBP &gt;=110 mmHg.</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS with LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Alone</title>
            <description>Amlodipine 5mg monotherapy</description>
          </group>
          <group group_id="O2">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Blood Pressure Categories at 4 Weeks</title>
          <description>BP optimal: SBP &lt;120 mmHg and DBP &lt;80 mmHg, BP normal: SBP &lt;130 mmHg and DBP &lt;85 mmHg but not optimal, BP high-normal: SBP &lt;140 mmHg and DBP &lt;90 mmHg but not normal. Grade 1 hypertension: SBP &lt;160 mmHg and DBP &lt;100 mmHg but not high-normal, Grade 2 hypertension: SBP &lt;180 mmHg and DBP &lt;110 mmHg but not grade 1, Grade 3 hypertension: SBP &gt;=180 mmHg or DBP &gt;=110 mmHg.</description>
          <population>FAS with LOCF</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BP optimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BP high-normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Relevant Abnormalities for Physical Examination, Pulse Rate, Laboratory Parameters and ECG.</title>
        <description>Clinically relevant abnormalities for Physical examination, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
        <time_frame>From drug administration until end of treatment plus one day</time_frame>
        <population>Treated set included patients who were randomised and took at least one dose of the trial medication in the double-blind treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>A5 Alone</title>
            <description>Amlodipine 5mg monotherapy</description>
          </group>
          <group group_id="O2">
            <title>T80/A5</title>
            <description>Telmisartan 80mg plus Amlodipine 5mg fixed-dose combination</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Relevant Abnormalities for Physical Examination, Pulse Rate, Laboratory Parameters and ECG.</title>
          <description>Clinically relevant abnormalities for Physical examination, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
          <population>Treated set included patients who were randomised and took at least one dose of the trial medication in the double-blind treatment period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Atrial fibrilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial ischaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood glucose increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein urine present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood creatinine phosphokinase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood creatinine increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood glucose abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>A5 Alone</title>
          <description>Amlodipine 5 mg one daily</description>
        </group>
        <group group_id="E2">
          <title>T80/A5</title>
          <description>Telmisartan 80 mg plus Amlodipine 5 mg once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

